Literature DB >> 26582821

Immature myeloid Gr-1+ CD11b+ cells from lipopolysaccharide-immunosuppressed mice acquire inhibitory activity in the bone marrow and migrate to lymph nodes to exert their suppressive function.

Veronica I Landoni1, Daiana Martire-Greco1, Nahuel Rodriguez-Rodrigues1, Paula Chiarella1, Pablo Schierloh1, Martin A Isturiz1, Gabriela C Fernández2.   

Abstract

Secondary infections due to post-sepsis immunosuppression are a major cause of death in patients with sepsis. Repetitive inoculation of increasing doses of lipopolysaccharide (LPS) into mice mimics the immunosuppression associated with sepsis. Myeloid-derived suppressor cells (MDSCs, Gr-1(+) CD11b(+)) are considered a major component of the immunosuppressive network, interfering with T-cell responses in many pathological conditions. We used LPS-immunosuppressed (IS) mice to address whether MDSCs acquired their suppressive ability in the bone marrow (BM) and whether they could migrate to lymph nodes (LNs) to exert their suppressive function. Our results showed that Gr-1(+) CD11b(+) cells of IS mice already had the potential to inhibit T-cell proliferation in the BM. Moreover, soluble factors present in the BM from IS mice were responsible for inducing this inhibitory ability in control BM cells. In addition, migration of Gr-1(+) CD11b(+) to LNs in vivo was maximal when cells obtained from the BM of IS mice were inoculated into an IS context. In this regard, we found chemoattractant activity in cell-free LN extracts (LNEs) from IS mice and an increased expression of the LN-homing chemokine receptor C-C chemokine receptor type 7 (CCR7) in IS BM Gr-1(+) CD11b(+) cells. These results indicate that Gr-1(+) CD11b(+) cells found in BM from IS mice acquire their suppressive activity in the same niche where they are generated, and migrate to LNs to exert their inhibitory role. A better understanding of MDSC generation and/or regulation of factors able to induce their inhibitory function may provide new and more effective tools for the treatment of sepsis-associated immunosuppression.
© 2016 Authors; published by Portland Press Limited.

Entities:  

Keywords:  MDSC; bone marrow; immunosuppression; lipopolysaccharide; mice; sepsis

Mesh:

Substances:

Year:  2015        PMID: 26582821     DOI: 10.1042/CS20150653

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

Review 1.  Advances in the understanding and treatment of sepsis-induced immunosuppression.

Authors:  Fabienne Venet; Guillaume Monneret
Journal:  Nat Rev Nephrol       Date:  2017-12-11       Impact factor: 28.314

2.  The novel α-glucan YCP improves the survival rates and symptoms in septic mice by regulating myeloid-derived suppressor cells.

Authors:  Dan Liu; Ming You; Guang-Feng Zhao; Xiu-Jun Li; Yu-Xian Song; Huan Dou; Wen-Bing Yao; Xiang-Dong Gao; Ya-Yi Hou
Journal:  Acta Pharmacol Sin       Date:  2017-06-26       Impact factor: 6.150

3.  Increased Levels of Pro-Inflammatory and Anti-Inflammatory Cellular Responses in Parkinson's Disease Patients: Search for a Disease Indicator.

Authors:  Likun Yang; Changfeng Guo; Jie Zhu; Yi Feng; Weiliang Chen; Zhizhong Feng; Dan Wang; Shibai Sun; Wei Lin; Yuhai Wang
Journal:  Med Sci Monit       Date:  2017-06-18

4.  Ferumoxytol Attenuates the Function of MDSCs to Ameliorate LPS-Induced Immunosuppression in Sepsis.

Authors:  Yaxian Xue; Yujun Xu; Xinghan Liu; Zhiheng Sun; Yuchen Pan; Xia Lu; Huaping Liang; Huan Dou; Yayi Hou
Journal:  Nanoscale Res Lett       Date:  2019-12-16       Impact factor: 4.703

5.  Early Activation of Myeloid-Derived Suppressor Cells Participate in Sepsis-Induced Immune Suppression via PD-L1/PD-1 Axis.

Authors:  Wei-Shuyi Ruan; Meng-Xiao Feng; Jia Xu; Ying-Ge Xu; Cong-Ying Song; Li-Ying Lin; Li Li; Yuan-Qiang Lu
Journal:  Front Immunol       Date:  2020-07-03       Impact factor: 7.561

Review 6.  Sepsis-induced immunosuppression: mechanisms, diagnosis and current treatment options.

Authors:  Di Liu; Si-Yuan Huang; Jian-Hui Sun; Hua-Cai Zhang; Qing-Li Cai; Chu Gao; Li Li; Ju Cao; Fang Xu; Yong Zhou; Cha-Xiang Guan; Sheng-Wei Jin; Jin Deng; Xiang-Ming Fang; Jian-Xin Jiang; Ling Zeng
Journal:  Mil Med Res       Date:  2022-10-09
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.